EP2177275A1 - Pump dispenser for the titration of pharmaceuticals - Google Patents
Pump dispenser for the titration of pharmaceuticals Download PDFInfo
- Publication number
- EP2177275A1 EP2177275A1 EP09013034A EP09013034A EP2177275A1 EP 2177275 A1 EP2177275 A1 EP 2177275A1 EP 09013034 A EP09013034 A EP 09013034A EP 09013034 A EP09013034 A EP 09013034A EP 2177275 A1 EP2177275 A1 EP 2177275A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- dosage
- dispensing
- kit according
- pharmaceutical
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000004448 titration Methods 0.000 title claims abstract description 39
- 239000003814 drug Substances 0.000 title description 10
- 239000007788 liquid Substances 0.000 claims abstract description 29
- 239000000544 cholinesterase inhibitor Substances 0.000 claims description 6
- OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 claims description 6
- 229950004543 neramexane Drugs 0.000 claims description 6
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 229960004640 memantine Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims description 4
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims description 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 3
- 229940123859 Nicotinic receptor antagonist Drugs 0.000 claims description 2
- 239000003367 nicotinic antagonist Substances 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims 1
- 108091006146 Channels Proteins 0.000 description 10
- 239000004480 active ingredient Substances 0.000 description 9
- -1 refleponide Chemical compound 0.000 description 8
- 239000012530 fluid Substances 0.000 description 7
- 230000001771 impaired effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 5
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 4
- 244000273618 Sphenoclea zeylanica Species 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229960001685 tacrine Drugs 0.000 description 4
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 4
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 108010025020 Nerve Growth Factor Proteins 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- MYDMWESTDPJANS-UHFFFAOYSA-N 2-amino-7-phosphonoheptanoic acid Chemical compound OC(=O)C(N)CCCCCP(O)(O)=O MYDMWESTDPJANS-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- VWLHWLSRQJQWRG-UHFFFAOYSA-O Edrophonum Chemical compound CC[N+](C)(C)C1=CC=CC(O)=C1 VWLHWLSRQJQWRG-UHFFFAOYSA-O 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 2
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 229960003748 edrophonium Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 2
- 229960001697 physostigmine Drugs 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229960002290 pyridostigmine Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229960004136 rivastigmine Drugs 0.000 description 2
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- 229960001278 teniposide Drugs 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- TWUSDDMONZULSC-HZMBPMFUSA-N (1r,2s)-2-(tert-butylamino)-1-(2,5-dimethoxyphenyl)propan-1-ol Chemical compound COC1=CC=C(OC)C([C@@H](O)[C@H](C)NC(C)(C)C)=C1 TWUSDDMONZULSC-HZMBPMFUSA-N 0.000 description 1
- NXWGWUVGUSFQJC-GFCCVEGCSA-N (2r)-1-[(2-methyl-1h-indol-4-yl)oxy]-3-(propan-2-ylamino)propan-2-ol Chemical compound CC(C)NC[C@@H](O)COC1=CC=CC2=C1C=C(C)N2 NXWGWUVGUSFQJC-GFCCVEGCSA-N 0.000 description 1
- GUHPRPJDBZHYCJ-SECBINFHSA-N (2s)-2-(5-benzoylthiophen-2-yl)propanoic acid Chemical compound S1C([C@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CC=C1 GUHPRPJDBZHYCJ-SECBINFHSA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 description 1
- XUKUURHRXDUEBC-SVBPBHIXSA-N (3s,5s)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SVBPBHIXSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- KOHIRBRYDXPAMZ-YHBROIRLSA-N (S,R,R,R)-nebivolol Chemical compound C1CC2=CC(F)=CC=C2O[C@H]1[C@H](O)CNC[C@@H](O)[C@H]1OC2=CC=C(F)C=C2CC1 KOHIRBRYDXPAMZ-YHBROIRLSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108010058207 Anistreplase Proteins 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- JOATXPAWOHTVSZ-UHFFFAOYSA-N Celiprolol Chemical compound CCN(CC)C(=O)NC1=CC=C(OCC(O)CNC(C)(C)C)C(C(C)=O)=C1 JOATXPAWOHTVSZ-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 108010056764 Eptifibatide Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- XQLWNAFCTODIRK-UHFFFAOYSA-N Gallopamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC(OC)=C(OC)C(OC)=C1 XQLWNAFCTODIRK-UHFFFAOYSA-N 0.000 description 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
- 108010072051 Glatiramer Acetate Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229940127337 Glycine Antagonists Drugs 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 1
- 229960000446 abciximab Drugs 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 229960004892 acemetacin Drugs 0.000 description 1
- FSQKKOOTNAMONP-UHFFFAOYSA-N acemetacin Chemical compound CC1=C(CC(=O)OCC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 FSQKKOOTNAMONP-UHFFFAOYSA-N 0.000 description 1
- 229960002054 acenocoumarol Drugs 0.000 description 1
- VABCILAOYCMVPS-UHFFFAOYSA-N acenocoumarol Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=C([N+]([O-])=O)C=C1 VABCILAOYCMVPS-UHFFFAOYSA-N 0.000 description 1
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 229960000983 anistreplase Drugs 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- BFNCJMURTMZBTE-UHFFFAOYSA-N aptiganel Chemical compound CCC1=CC=CC(N(C)C(N)=NC=2C3=CC=CC=C3C=CC=2)=C1 BFNCJMURTMZBTE-UHFFFAOYSA-N 0.000 description 1
- 229950001180 aptiganel Drugs 0.000 description 1
- 229960003856 argatroban Drugs 0.000 description 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- 229960004277 benorilate Drugs 0.000 description 1
- FEJKLNWAOXSSNR-UHFFFAOYSA-N benorilate Chemical compound C1=CC(NC(=O)C)=CC=C1OC(=O)C1=CC=CC=C1OC(C)=O FEJKLNWAOXSSNR-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960004324 betaxolol Drugs 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229960002781 bisoprolol Drugs 0.000 description 1
- VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 description 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 description 1
- 229960001500 bivalirudin Drugs 0.000 description 1
- 108010055460 bivalirudin Proteins 0.000 description 1
- 229960003655 bromfenac Drugs 0.000 description 1
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 229960001222 carteolol Drugs 0.000 description 1
- LWAFSWPYPHEXKX-UHFFFAOYSA-N carteolol Chemical compound N1C(=O)CCC2=C1C=CC=C2OCC(O)CNC(C)(C)C LWAFSWPYPHEXKX-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229960002320 celiprolol Drugs 0.000 description 1
- 229960005110 cerivastatin Drugs 0.000 description 1
- SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960003728 ciclesonide Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004588 cilostazol Drugs 0.000 description 1
- RRGUKTPIGVIEKM-UHFFFAOYSA-N cilostazol Chemical compound C=1C=C2NC(=O)CCC2=CC=1OCCCCC1=NN=NN1C1CCCCC1 RRGUKTPIGVIEKM-UHFFFAOYSA-N 0.000 description 1
- 229960002174 ciprofibrate Drugs 0.000 description 1
- KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000013409 condiments Nutrition 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 1
- 229950004794 dizocilpine Drugs 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- GLGOPUHVAZCPRB-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CN=C2[C]1C=CC=C2 GLGOPUHVAZCPRB-LROMGURASA-N 0.000 description 1
- 229960003745 esmolol Drugs 0.000 description 1
- AQNDDEOPVVGCPG-UHFFFAOYSA-N esmolol Chemical compound COC(=O)CCC1=CC=C(OCC(O)CNC(C)C)C=C1 AQNDDEOPVVGCPG-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- 229960004945 etoricoxib Drugs 0.000 description 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002714 fluticasone Drugs 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 229960003765 fluvastatin Drugs 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 229960000457 gallopamil Drugs 0.000 description 1
- 229960003627 gemfibrozil Drugs 0.000 description 1
- 229960003776 glatiramer acetate Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 1
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 1
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960004752 ketorolac Drugs 0.000 description 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 1
- 229960004340 lacidipine Drugs 0.000 description 1
- GKQPCPXONLDCMU-CCEZHUSRSA-N lacidipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OCC)C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C GKQPCPXONLDCMU-CCEZHUSRSA-N 0.000 description 1
- 229960004408 lepirudin Drugs 0.000 description 1
- OTQCKZUSUGYWBD-BRHMIFOHSA-N lepirudin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)[C@@H](C)O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 OTQCKZUSUGYWBD-BRHMIFOHSA-N 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 229960002373 loxoprofen Drugs 0.000 description 1
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 1
- 229960000994 lumiracoxib Drugs 0.000 description 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 229960003134 mepindolol Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- CLUKHUGGXSIGRX-UHFFFAOYSA-N methanesulfonic acid;1,3,3,5,5-pentamethylcyclohexan-1-amine Chemical compound CS(O)(=O)=O.CC1(C)CC(C)(C)CC(C)(N)C1 CLUKHUGGXSIGRX-UHFFFAOYSA-N 0.000 description 1
- VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002704 metipranolol Drugs 0.000 description 1
- BLWNYSZZZWQCKO-UHFFFAOYSA-N metipranolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC(C)=C(OC(C)=O)C(C)=C1C BLWNYSZZZWQCKO-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 229960001664 mometasone Drugs 0.000 description 1
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000006070 nanosuspension Substances 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960000619 nebivolol Drugs 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 229960000227 nisoldipine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229960005425 nitrendipine Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229960004662 parecoxib Drugs 0.000 description 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
- 229960002035 penbutolol Drugs 0.000 description 1
- KQXKVJAGOJTNJS-HNNXBMFYSA-N penbutolol Chemical compound CC(C)(C)NC[C@H](O)COC1=CC=CC=C1C1CCCC1 KQXKVJAGOJTNJS-HNNXBMFYSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- 229960000280 phenindione Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- 229960004923 phenprocoumon Drugs 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229960001237 podophyllotoxin Drugs 0.000 description 1
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 1
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960001455 quinapril Drugs 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 229960002917 reteplase Drugs 0.000 description 1
- 108010051412 reteplase Proteins 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229960000371 rofecoxib Drugs 0.000 description 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
- 150000003902 salicylic acid esters Chemical class 0.000 description 1
- 229960000953 salsalate Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 229960002370 sotalol Drugs 0.000 description 1
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960000103 thrombolytic agent Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229960001312 tiaprofenic acid Drugs 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960004605 timolol Drugs 0.000 description 1
- 229960003425 tirofiban Drugs 0.000 description 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- FQCQGOZEWWPOKI-UHFFFAOYSA-K trisalicylate-choline Chemical compound [Mg+2].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O FQCQGOZEWWPOKI-UHFFFAOYSA-K 0.000 description 1
- 230000036967 uncompetitive effect Effects 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960002769 zofenopril Drugs 0.000 description 1
- IAIDUHCBNLFXEF-MNEFBYGVSA-N zofenopril Chemical compound C([C@@H](C)C(=O)N1[C@@H](C[C@@H](C1)SC=1C=CC=CC=1)C(O)=O)SC(=O)C1=CC=CC=C1 IAIDUHCBNLFXEF-MNEFBYGVSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
- B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
- B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
- B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle
- B05B11/1001—Piston pumps
Definitions
- the present invention relates to a pharmaceutical kit comprising (i) a pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical (ii) said liquid or paste-like pharmaceutical contained in said pump dispenser and (iii) instructions for implementing a predetermined titration scheme, wherein said titration scheme comprises the dispensing of at least two different integer multiples of said predetermined base-dosage.
- the present invention also relates to the use of said kit for treating a patient.
- a desired dosage regime and/or a desired overall dosage cannot or should not be achieved in a single step but rather by means of incrementally increasing or decreasing the dosage from a certain predefined initial dosage to a certain predetermined final dosage and/or by means of dosing in intervals.
- titration This increase or decrease or alternating of dosages involving at least two dosages that are different from each other.
- the titration of solid tablets is known, for example by providing a tablet of a given dosage and further providing instructions to administer fractions or multiples of said one tablet.
- Titration packages comprising different tablets of increasing dosages (for example 5 mg, 10 mg, 15 mg, 20 mg) are also known from the art (see, e.g., US 2006/0278557 ).
- a titration package and method for enabling compliance with a regime of changing dosage of medication over a period of time is provided.
- the solid formulation package includes a backing having an array of receivers with the array including a plurality of columns and a plurality of rows.
- a plurality of sets of tablets are provided with each tablet in set having a common dose of medication and a different dose than a tablet of a different set.
- a solid formulation may not be available or may be difficult to implement.
- manufacturing and providing a large number of different tablets may be cumbersome and ineffective.
- at least four different tablets each having a different composition need to be manufactured and packaged/provided separately.
- a method of dosing liquids known in the art is a droplet dispenser.
- small droplets are dispensed out of a bottle having a comparatively small orifice.
- the volume of the droplet so dispensed is determined, within a certain margin of error, by the geometry of the orifice.
- a large number of droplets needs to be dispensed and counted, for example 20 droplets.
- multiples of a base-dosage would need to be dispensed rendering this system cumbersome and error-prone, for example for elderly and/or impaired patients.
- one object of the present invention is to provide a means for delivering a liquid or paste-like pharmaceutical to a patient in need thereof that allows for a high degree of flexibility in regard to how many and which multiples of a base-dosage can be administered and that allows for easy and safe dispensing of different dosages even if the patient is potentially impaired, for example in regard to vision or in regard to memory.
- Drawbacks and limitations posed by the prior art as discussed above should be avoided or minimized.
- a pharmaceutical kit comprising (i) a pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical (ii) said liquid or paste-like pharmaceutical contained in said pump dispenser and (iii) instructions for implementing a predetermined titration scheme, wherein said titration scheme comprises the dispensing of at least two different integer multiples of said predetermined base-dosage.
- said pump dispenser comprises at least a pump head and dispensing is achieved by means of actuating said pump head of said pump dispenser.
- said pump dispenser comprises at least one pump head and at least one reservoir attached thereto.
- Pump heads are easy to operate and are made, in one embodiment, big enough and ergonomically suitable for operation by elderly patients, visually impaired patients and/or patients who are impaired in regard to motion control.
- the pump head is of the "push-plunger'-type, i.e. comprises at least one plunger or piston or actuated pusher, i.e. actuator, and at least one sealed chamber in which a pressure can be built up by means of moving said plunger/piston/ actuator.
- said pump dispenser comprises at least one hollow body with a chamber of a defined inner volume and a defined inner diameter.
- said hollow body comprises a recess that has a diameter that is larger than said inner diameter of the chamber.
- said pump dispenser additionally comprises at least one ball acting as a one-way valve and at least one piston that runs inside said hollow body.
- the volume as defined by the chamber inside said hollow body of the dispenser head is more than 0.1 ml or more than 0.5 ml or more than 1 ml or more than 3 ml. In accordance with another embodiment, said volume ranges from 0.1 ml to 5.0 ml or from 0.3 ml to 3 ml or from 0.5 ml to 1 ml.
- the spout of the pump dispenser i.e. the part of the pump head out of which the liquid or paste-like pharmaceutical is ultimately expelled is arcuate, i.e. has at least one portion that is substantially parallel to the horizontal plane and has at least one other portion that is inclined in at least a 45 degree angle relative to said horizontal plane.
- the dispensing of the base-dosage is achieved by performing one stroke of an actuator or plunge or piston of the pump head.
- one stroke means one single stroke.
- said liquid or paste-like pharmaceutical comprises at least one NMDA receptor antagonist and/or at least one acetylcholinesterase inhibitor and/or at least one ⁇ 9 / ⁇ 10 nicotinic receptor antagonist.
- said liquid or paste-like pharmaceutical comprises at least memantine and/or neramexane and/or pharmaceutically acceptable salts thereof such as memantine HCl or neramexane mesylate.
- said titration scheme comprises at least one up-titration step, i.e. comprises the dispensing of at least two or at least three or at least four increasing integer multiples of said predetermined base-dosage, for example the dispensing of at least two increasing integers of the base-dosage with said integer starting at 1.
- said titration scheme comprises the dispensing of at least two or at least three or at least four decreasing integer multiples of said predetermined base-dosage.
- Such a titration scheme may be used for decreasing the dosage to a certain predetermined final dosage (such as for a maintenance therapy).
- the scheme may comprise at first the dispensing of an integer multiple n 1 of a base-dosage and consecutively dispensing an integer multiple n 2 , wherein n 2 ⁇ n 1 .
- said titration scheme comprises the dispensing of at least two or at least three or at least four alternating dosages that are different from each other.
- Such a titration scheme may be used for alternating between certain predetermined dosages (such as for an interval therapy).
- each of the at least two different dosages are dispensed at least twice.
- an initial dosage may be administered for several consecutive days, including one week or more than a week, for example once daily for one week, before the next (different) dosage is administered, for example a higher or a lower or an alternating dosage, also for example once daily for one week.
- the kit as described in any one of the aforementioned embodiments is used for the treatment of a patient.
- "dispensing” means “actuating a pump dispenser”. This is achieved, in one embodiment, by means of actuating the pump head of the pump dispenser, for example by performing one complete or one incomplete stroke of the actuator or plunge or piston of the pump head.
- “one” means “one single”.
- predetermined base-dosage means one specific volume that is dispensed per (incomplete or complete) stroke, for example 0.25 ml or 0.3 ml or 0.5 ml or 1 ml or 2 ml or 3 ml or 5 ml. This volume is defined by the geometry of the pump dispenser, for example of the pump head and the volume of the hollow chamber formed therein. Said predetermined base-dosage cannot be adjusted or altered by the patient.
- an incomplete stroke of the actuator or plunge or piston of the pump head may also be sufficient, as long as the amount of fluid dispensed per (incomplete) stroke is the same or similar.
- titration occurs in at least two steps of administering consecutively increasing multiple integers of the base-dosage.
- Such a titration regime is referred to as "up-titra-tion " and may be used, for example, for administering memantine as the active ingredient.
- said integer is starting at 1, i.e. one time the base-dosage is administered, then two times the base-dosage etc.
- titration occurs in at least two steps of administering consecutive decreasing multiple integers of a base-dosage.
- the starting dosage may be 100 %, i.e. 4 times the base-dosage of 25 % while the following dosage is 75 %, i.e. 3 times the base-dosage of 25 %.
- Such a titration regime is referred to as "maintenance therapy" and may be used, for example, for administering neramexane or pharmaceutically acceptable salts thereof.
- titration occurs in at least three steps of administering consecutive multiple integers of the base-dosage.
- said integer starts at 1 and the dosage increases (i.e. 1 time the base-dosage, 2 times the base-dosage, 3 times the base-dosage, ...), while in another embodiment, the integer starts at a number ⁇ 3 and the dosage decreases (i.e. 3 times the base-dosage, 2 times the base-dosage, 1 time the base-dosage).
- titration occurs in at least four steps of administering consecutive multiple integers of the base-dosage with said integer starting at 1 (i.e. 1 time the base-dosage, 2 times the base-dosage, 3 times the base-dosage, 4 times the base-dosage or 4 times the base-dosage, then 3 times the base-dosage etc.), while in another embodiment, the integer starts at a number ⁇ 4 and the dosage correspondingly decreases.
- titration occurs in intervals with a high dosage and a subsequent lower dosage followed again by said high dosage etc.
- a practitioner prescribing the kit may devise individual titration schemes for individual patients while using one pump dispenser provided with one base-dosage that can therefore be manufactured and provided commercially at minimum operating expenses.
- Liquid or paste-like pharmaceuticals according to the present invention may be in the form of a solution, a dispersion or an emulsion (micro- or nano-emulsions, self-emulsifying system, multiple emulsions) or in the form of a gel, paste, suspension (micro- or nano-suspension), hydrosol, liposome, mixed micells or in other forms of colloidal disperse systems such as drug loaded microparticles, nanocapsules or nanoparticles dispersed in a colloidal system or solution.
- Paste-like masses may display a Newtonian or a non-Newtonian flow behaviour.
- Active pharmaceutical ingredients that may be administered in accordance with such a titration scheme are or may be the following active ingredients in liquid or in paste-like form: uncompetitive channel blockers (e.g. NMDAr antabonists, e.g. amantadine, dextromethorphan, ibogaine, ketamine, phencyclidine, riluzole, memantine, neramexane), antagonists at ⁇ 9 / ⁇ 10 nicotinic receptors (e.g. neramexane), non-competitive antagonists (e.g. dizocilpine, aptiganel, remacimide), glycine antagonists (e.g.
- NMDAr antabonists e.g. amantadine, dextromethorphan, ibogaine, ketamine, phencyclidine, riluzole, memantine, neramexane
- ACPC 1-aminocyclopropanecarboxylic acid
- competitive antagonists e.g. AP7 (2-amino-7-phosphonoheptanoic acid)
- thrombolytics e.g. reteplase, tenecteplase, anistreplase, streptokinase, urokinase
- anticoagulants e.g. heparin, warfarin, acenocoumarol, phenprocoumon, phenindione, argatroban, lepirudin, bivalirudin
- antibiotics corticosteroids
- antiplatelet agents e.g. aspirin, clopidogrel, ticlopidine, abciximab, eptifibatide, tirofiban, cilostazol
- non-stereoidal anti-inflammatories e.g. salicylates (e.g.
- arylalkanoic acids e.g. diclofenac, aceclofenac, acemetacin, bromfenac, etodolac, indometacin, nabumetone, sulindac, tometin
- 2-Arylpropionic acids profens
- ibuprofen carprofen, fenbufen, fenoporfen, flurbiprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin, tiaprofenic acid, suprofen), N-Arylanthranilic acids (fenamic acids) (e.g. mefenamic acid, meclofenamic acid), pyrazolidine derivates (e.g. phenylbutazone, azapropazone, metamizole, oxyphenbutazone, sulfinpyrazone), oxicams (e.g.
- COX-2 inhibitors e.g. celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib
- sulphonanilides e.g. nimesulide
- growth factors e.g.
- TGF- ⁇ transforming growth factor beta
- G-CSF granulocyte-colony stimulating factor
- GM-CSF granulocyte-macrophage colony stimulating factor
- NGF nerve growth factor
- PDGF platelet derived growth factor
- EPO erythropoietin
- TPO thrombopoietin
- GDF-9 growth differentiation factor-9
- aFGF or FGF-1 acidic fibroblast growth factor
- bFGF or FGF-2 basic fibroblast growth factor
- EGF epidermal growth factor
- HGF hepatocyte growth factor
- immunosuppressant drugs e.g.
- cyclosporine tacrolimus, prednisolone, azathioprine, sirolimus, mycopehnolate, glatiramer acetate
- antineoplastic agents alkylating agents (e.g. cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil), anti-metabolites (e.g. azathioprine, mercaptopurine, pyrimidine), vinca alkaloids (e.g. vincristine, vinblastine, vinorelbine, vindesine), podophyllotoxin (e.g. etoposide, teniposide), taxanes (e.g.
- paclitaxel paclitaxel
- topoisomerase inhibitors e.g. amsacrine, etoposide, etoposide phosphate, teniposide, camptothecins such as irinotecan, topotecan
- antitumor antibiotics e.g. dactinomycin
- monoclonal antibodies e.g. trastuzumab, cetuximab, rituximab, bevacizumab
- ACE-inhibitors e.g.
- captopril zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, fosinopril
- Acetylcholinesterase Inhibitors e.g. donepezil, rivastigmine, pyridostigmine, tetrahydroaminoacridine physostigmine, galantamine, tacrine, edrophonium, neostigmine
- HMG-coA reductase inhibitors e.g.
- atorvastatin cerivastatin, fluvastatin, lovastatin, pravastatin, simvastatin
- beta-blockers e.g. alprenolol, carteolol, levobunolol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, acebutolol, atenolol, betaxolol, bisoprolol, esmolol, metoprolol, nebivolol, carvedilol, celiprolol, lavetalol, butaxamin), calcium channel blockers (e.g.
- nimodipine amlodipine, felodipine, nicardipine, nifedipine, nisoldipine, nitrendipine, lacidipine, lercandipine
- long acting nitrates e.g. isosorbide dinitrate and mononitrate, nitroglycerin
- cholesterol-lowering agents e.g. bezafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate.
- the kit comprising a liquid or paste-like pharmaceutical comprises at least one NMDA receptor antagonist.
- NMDAr antagonists may be compositions comprising, as pharmaceutically active ingredients, memantine or neramexane or pharmaceutically acceptable salts thereof.
- kits comprising a liquid or paste-like pharmaceutical comprising at least one acetylcholinesterase inhibitor (AchEI).
- acetylcholinesterase inhibitors may be compositions comprising, among others, donepezil, rivastigmine, pyridostigmine, tetrahydroaminoacridine, physostigmine, galantamine, tacrine, edrophonium, neostigmine and pharmaceutically acceptable salts thereof.
- the fluid, liquid or paste-like substance may include any other solvent, solute, additive, adjuvant or excipient that is pharmaceutically acceptable.
- solvent(s) water and alcohol, or mixtures thereof, are used as solvent(s).
- Pump dispensers for dispensing liquids, viscous or paste-like masses, for example soap, lotion or condiments are known form the art.
- a simple-to-operate push plunger housed in a container is known, for example, from US 3 463 093 .
- Another example of a general use dispensing unit is given in US 5 326 000 .
- a dispenser or delivery apparatus for flowable media, particularly very viscous or gel-like media, specifically also comprising pharmaceuticals is disclosed in US 4 728 008 .
- the pump dispenser comprises at least one pump head and at least one reservoir attached thereto.
- the pump head is of the "push-plunger"-type, i.e. comprises at least one plunger or piston or actuated pusher (actuator) and at least one sealed chamber in which a pressure can be built up by means of moving said plunger/piston/actuator.
- Dispensing by means of the "push-plunger"-principle is seen as particularly advantageous for operation of the dispenser by visually impaired patients or patients having coordination/motion control issues as is typical for some of the indications in accordance with the present invention, for example dementia, glaucoma, Alzheimer's disease etc.
- Droplet dispensers for liquids as known from pharmaceutical applications employing measuring spoons and/or narrow spouts for "counting" droplets are much less suitable for these indications/applications than the pump dispenser and kit in accordance with the present invention.
- the pump dispenser dispenses said predetermined base-dosage essentially independent of the actuation path, and/or irrespective of how far the pump head has been actuated.
- the amount of dispensed fluid is independent of how far the pump head (or, more specifically, the plunger) has been actuated once a predetermined threshold of the actuation path has been passed.
- said threshold is defined by a recess in a chamber of the pump head of the dispenser.
- the pump head comprises at least one hollow body (15) with a chamber (19) of a given inner diameter d 15 .
- This chamber contains the substance to be dispensed during the next cycle.
- This hollow body (15) also comprises a recess (20) with a diameter larger than d 15 .
- the hollow body furthermore comprises a conical seat and a second channel (22). This second channel is connected to a larger reservoir of the substance to be dispensed, i.e. the reservoir of the overall dispenser.
- a ball (21) is located in a conical seat of hollow body (15). Said ball (21) acts as a one-way valve and may seal off the second channel (22). Inside the hollow body (15) runs a piston (17) with a hollow stem (18) and an elastic lip at the lower end of piston (17).
- the hollow stem (18) comprises a first channel (27).
- a first spring (24) is provided between piston (17) and a shoulder of the hollow body (15). Said first spring (24) drives the piston away from the above-discussed reservoir.
- the hollow stem (18) has a compartment at its top to house the cone (28) and a second spring (29). This small compartment is open (35) to lead to any tube or applicator or spout for actually dispensing the fluid. Cone (28) is loaded by this second spring (29) and will close channel (27). Further details can be taken from Figure 1 .
- the cycle of dispensing the substance and refilling chamber (19) can be achieved as follows. Initially, chamber (19) is filled with the pharmaceutical substance to be dispensed. Springs (24) and (29) are not fully expanded. The second and first channels (22) and (27) are closed. The dispensing cycle is started by pushing the stem (18) into the hollow body (15). Meanwhile, piston (17) is driven further into the hollow body (15) thus increasing the chamber pressure. At the same time, spring (24) is being compressed.
- the second spring (29) yields to said chamber pressure.
- This "yielding" can be adjusted (or "predetermined") by choosing an appropriate second spring (29).
- the cone (28) opens the first channel (27).
- the pharmaceutical substance now flows out of chamber (19) through first channel (27) and opening (35), driven by the chamber pressure.
- the second spring (29) reaches the recess (20) the chamber pressure collapses.
- the dose (volume) of the supplied substance is determined by the inner diameter d 15 of hollow body (15) and the distance covered by piston (17) before reaching the annular recess (20).
- first spring (24) will push piston (17) upwards along the hollow body (15). On its way up the elastic lower lip of piston (17) will exit the annular recess (20) and reengage with the inner diameter of the chamber (19) thus sealing said chamber. Further travel of piston (17) causes the chamber pressure to drop further.
- the reduced chamber pressure allows ball (21) to leave its conical seat, i.e. opens up the seal.
- the reduced chamber pressure draws fresh liquid or paste from the large reservoir into chamber (19) until the shoulder of stem (18) makes contact with bar (52). This contact of stem (18) and the bar (52) ends the cycle of operation.
- the pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical comprises at least one pump head comprising a hollow body with a chamber of a defined inner volume and a defined inner diameter, wherein the hollow body further comprises a recess that has a diameter that is larger than said inner diameter of the chamber.
- the overall dispensed volume per stroke i.e. the volume of the predetermined base-dosage
- the volume as defined by the chamber inside the hollow body of the dispenser head is more than 0.3 ml, more than 0.5 ml or more than 1 ml.
- the concentration of the active ingredient in said predetermined dispensed volume is comparatively low, for example lower than 50 % (by volume), lower than 10 % or lower than 5 % or lower than 1 %.
- concentration of the active ingredient in said predetermined dispensed volume is comparatively low, for example lower than 50 % (by volume), lower than 10 % or lower than 5 % or lower than 1 %.
- 5 mg of active ingredient may be present in a base-dosage of 0.5 ml (resulting in a 1 % solution).
- any possible variation in dispensed volume per successive stroke translates only into a small variation in dispensed active ingredient, i.e. in base-dosage.
- Commonly used droplet bottles for dispensing liquid pharmaceuticals comprise a particularly narrow opening or spout through which only small droplets can be expelled. Due to the geometric constraint of the small opening and the action of surface tension, the volume of these small droplets is comparatively constant, albeit very small. In order to compensate for volume fluctuations and in order to achieve a final volume that can be reasonably administered, for example in a spoon, a large number of these small droplets needs to be dispensed in order to arrive at the one pre-described dosage, for example 20 droplets or 30 droplets.
- This administration scheme has a couple of draw-backs, in particular the requirement to count a large number of droplets. Therefore, such an administration scheme is not suitable for patients that are physically and/or mentally impaired.
- the presently described pump-dispenser is designed to have an easy-to-use actuation head (as known, for example, from everyday usage soap dispensers) while dispensing the required base-dosage in one stroke.
- an easy-to-use actuation head as known, for example, from everyday usage soap dispensers
- this may be achieved in the comparatively small number of two or three strokes (using a droplet-based dispenser as described above, for example the dispensing of two or three times 20 droplets would be required to achieve the same result).
- the spout of the pump dispenser i.e. the part of the pump head out of which the liquid, viscous or paste-like pharmaceutical is ultimately expelled is arcuate, i.e. has at least one portion that is substantially parallel in the horizontal direction and has at least one portion that is inclined in at least a 45 degree angle relative to the horizontal plane.
- This arcuate spout allows for a less spill-prone dispensing and is of particular advantage if the user of the dispenser is an older, handicapped or visually impaired patient.
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a pharmaceutical kit comprising (i) a pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical (ii) said liquid or paste-like pharmaceutical contained in said pump dispenser and (iii) instructions for implementing a predetermined titration scheme, wherein said titration scheme comprises the dispensing of at least two different integer multiples of said predetermined base-dosage. The present invention also relates to the use of such a kit for the treatment of a patient.
Description
- The present invention relates to a pharmaceutical kit comprising (i) a pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical (ii) said liquid or paste-like pharmaceutical contained in said pump dispenser and (iii) instructions for implementing a predetermined titration scheme, wherein said titration scheme comprises the dispensing of at least two different integer multiples of said predetermined base-dosage.
- The present invention also relates to the use of said kit for treating a patient.
- For certain pharmaceutical compositions, a desired dosage regime and/or a desired overall dosage cannot or should not be achieved in a single step but rather by means of incrementally increasing or decreasing the dosage from a certain predefined initial dosage to a certain predetermined final dosage and/or by means of dosing in intervals.
- This increase or decrease or alternating of dosages involving at least two dosages that are different from each other is referred to as "titration" in the following.
- In the prior art, the titration of solid tablets is known, for example by providing a tablet of a given dosage and further providing instructions to administer fractions or multiples of said one tablet.
- Titration packages comprising different tablets of increasing dosages (for example 5 mg, 10 mg, 15 mg, 20 mg) are also known from the art (see, e.g.,
US 2006/0278557 ). Therein, a titration package and method for enabling compliance with a regime of changing dosage of medication over a period of time is provided. The solid formulation package includes a backing having an array of receivers with the array including a plurality of columns and a plurality of rows. A plurality of sets of tablets are provided with each tablet in set having a common dose of medication and a different dose than a tablet of a different set. - In some cases, however, a solid formulation may not be available or may be difficult to implement. Also, in case the titration scheme comprises a large number of different dosages, manufacturing and providing a large number of different tablets may be cumbersome and ineffective. For example, according to
US 2006/0278557 , at least four different tablets each having a different composition need to be manufactured and packaged/provided separately. - A method of dosing liquids known in the art is a droplet dispenser. Therein, small droplets are dispensed out of a bottle having a comparatively small orifice. The volume of the droplet so dispensed is determined, within a certain margin of error, by the geometry of the orifice. In order to average fluctuations in the droplet volume, a large number of droplets needs to be dispensed and counted, for example 20 droplets. In order to achieve titration, multiples of a base-dosage would need to be dispensed rendering this system cumbersome and error-prone, for example for elderly and/or impaired patients.
- Therefore, one object of the present invention is to provide a means for delivering a liquid or paste-like pharmaceutical to a patient in need thereof that allows for a high degree of flexibility in regard to how many and which multiples of a base-dosage can be administered and that allows for easy and safe dispensing of different dosages even if the patient is potentially impaired, for example in regard to vision or in regard to memory. Drawbacks and limitations posed by the prior art as discussed above should be avoided or minimized.
- This object, among others, is solved by a pharmaceutical kit comprising (i) a pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical (ii) said liquid or paste-like pharmaceutical contained in said pump dispenser and (iii) instructions for implementing a predetermined titration scheme, wherein said titration scheme comprises the dispensing of at least two different integer multiples of said predetermined base-dosage.
- This object is also solved by the use of said kit for treating a patient.
- In accordance with one embodiment of the present invention, said pump dispenser comprises at least a pump head and dispensing is achieved by means of actuating said pump head of said pump dispenser.
- In accordance with another embodiment of the present invention, said pump dispenser comprises at least one pump head and at least one reservoir attached thereto. Pump heads are easy to operate and are made, in one embodiment, big enough and ergonomically suitable for operation by elderly patients, visually impaired patients and/or patients who are impaired in regard to motion control.
- In accordance with another embodiment of the present invention, the pump head is of the "push-plunger'-type, i.e. comprises at least one plunger or piston or actuated pusher, i.e. actuator, and at least one sealed chamber in which a pressure can be built up by means of moving said plunger/piston/ actuator.
- In accordance with another embodiment of the present invention said pump dispenser comprises at least one hollow body with a chamber of a defined inner volume and a defined inner diameter. In accordance with one embodiment of the present invention, said hollow body comprises a recess that has a diameter that is larger than said inner diameter of the chamber.
- In accordance with another embodiment of the present invention, said pump dispenser additionally comprises at least one ball acting as a one-way valve and at least one piston that runs inside said hollow body.
- In accordance with another embodiment of the present invention, the volume as defined by the chamber inside said hollow body of the dispenser head is more than 0.1 ml or more than 0.5 ml or more than 1 ml or more than 3 ml. In accordance with another embodiment, said volume ranges from 0.1 ml to 5.0 ml or from 0.3 ml to 3 ml or from 0.5 ml to 1 ml.
- In accordance with yet another embodiment of the present invention, the spout of the pump dispenser, i.e. the part of the pump head out of which the liquid or paste-like pharmaceutical is ultimately expelled is arcuate, i.e. has at least one portion that is substantially parallel to the horizontal plane and has at least one other portion that is inclined in at least a 45 degree angle relative to said horizontal plane.
- In accordance with another embodiment of the present invention, the dispensing of the base-dosage is achieved by performing one stroke of an actuator or plunge or piston of the pump head. Therein, "one stroke" means one single stroke.
- In accordance with one embodiment of the present invention, said liquid or paste-like pharmaceutical comprises at least one NMDA receptor antagonist and/or at least one acetylcholinesterase inhibitor and/or at least one α9/α10 nicotinic receptor antagonist.
- In accordance with one embodiment of the present invention, said liquid or paste-like pharmaceutical comprises at least memantine and/or neramexane and/or pharmaceutically acceptable salts thereof such as memantine HCl or neramexane mesylate.
- In accordance with one embodiment of the present invention, said titration scheme comprises at least one up-titration step, i.e. comprises the dispensing of at least two or at least three or at least four increasing integer multiples of said predetermined base-dosage, for example the dispensing of at least two increasing integers of the base-dosage with said integer starting at 1.
- In accordance with one embodiment of the present invention, said titration scheme comprises the dispensing of at least two or at least three or at least four decreasing integer multiples of said predetermined base-dosage. Such a titration scheme may be used for decreasing the dosage to a certain predetermined final dosage (such as for a maintenance therapy). The scheme may comprise at first the dispensing of an integer multiple n1 of a base-dosage and consecutively dispensing an integer multiple n2, wherein n2 < n1.
- In accordance with one embodiment of the present invention, said titration scheme comprises the dispensing of at least two or at least three or at least four alternating dosages that are different from each other. Such a titration scheme may be used for alternating between certain predetermined dosages (such as for an interval therapy). In one embodiment, each of the at least two different dosages are dispensed at least twice.
- Any of the titration schemes is to be understood that an initial dosage may be administered for several consecutive days, including one week or more than a week, for example once daily for one week, before the next (different) dosage is administered, for example a higher or a lower or an alternating dosage, also for example once daily for one week.
- In accordance with one embodiment of the present invention, the kit as described in any one of the aforementioned embodiments is used for the treatment of a patient.
- In accordance with one embodiment of the present invention, "dispensing" means "actuating a pump dispenser". This is achieved, in one embodiment, by means of actuating the pump head of the pump dispenser, for example by performing one complete or one incomplete stroke of the actuator or plunge or piston of the pump head. Therein, "one" means "one single".
- In accordance with one embodiment of the present invention, "predetermined" base-dosage means one specific volume that is dispensed per (incomplete or complete) stroke, for example 0.25 ml or 0.3 ml or 0.5 ml or 1 ml or 2 ml or 3 ml or 5 ml. This volume is defined by the geometry of the pump dispenser, for example of the pump head and the volume of the hollow chamber formed therein. Said predetermined base-dosage cannot be adjusted or altered by the patient.
- In accordance with one embodiment, an incomplete stroke of the actuator or plunge or piston of the pump head may also be sufficient, as long as the amount of fluid dispensed per (incomplete) stroke is the same or similar. Mechanisms ensuring such a repetitively stable modus of dispensing are described below, for example starting in paragraph [0046].
- In one embodiment according to the present invention, titration occurs in at least two steps of administering consecutively increasing multiple integers of the base-dosage. Such a titration regime is referred to as "up-titra-tion" and may be used, for example, for administering memantine as the active ingredient. In a specific embodiment, said integer is starting at 1, i.e. one time the base-dosage is administered, then two times the base-dosage etc.
- In another embodiment according to the present invention, titration occurs in at least two steps of administering consecutive decreasing multiple integers of a base-dosage. For example, the starting dosage may be 100 %, i.e. 4 times the base-dosage of 25 % while the following dosage is 75 %, i.e. 3 times the base-dosage of 25 %. Such a titration regime is referred to as "maintenance therapy" and may be used, for example, for administering neramexane or pharmaceutically acceptable salts thereof.
- In a specific embodiment according to the present invention, titration occurs in at least three steps of administering consecutive multiple integers of the base-dosage. According to one embodiment, said integer starts at 1 and the dosage increases (i.e. 1 time the base-dosage, 2 times the base-dosage, 3 times the base-dosage, ...), while in another embodiment, the integer starts at a number ≥ 3 and the dosage decreases (i.e. 3 times the base-dosage, 2 times the base-dosage, 1 time the base-dosage).
- In yet another embodiment according to the present invention, titration occurs in at least four steps of administering consecutive multiple integers of the base-dosage with said integer starting at 1 (i.e. 1 time the base-dosage, 2 times the base-dosage, 3 times the base-dosage, 4 times the base-dosage or 4 times the base-dosage, then 3 times the base-dosage etc.), while in another embodiment, the integer starts at a number ≥ 4 and the dosage correspondingly decreases.
- In yet another embodiment of the invention, titration occurs in intervals with a high dosage and a subsequent lower dosage followed again by said high dosage etc.
- As can be seen from the above, implementing various titration schemes by means of using one pump dispenser and simply varying the number of strokes is possible, while, at the same type working with only one base-dosage of the pharmaceutical composition (having a predetermined concentration in regard to the active ingredient).
- ln accordance with the present invention, a practitioner prescribing the kit may devise individual titration schemes for individual patients while using one pump dispenser provided with one base-dosage that can therefore be manufactured and provided commercially at minimum operating expenses.
- Liquid or paste-like pharmaceuticals according to the present invention may be in the form of a solution, a dispersion or an emulsion (micro- or nano-emulsions, self-emulsifying system, multiple emulsions) or in the form of a gel, paste, suspension (micro- or nano-suspension), hydrosol, liposome, mixed micells or in other forms of colloidal disperse systems such as drug loaded microparticles, nanocapsules or nanoparticles dispersed in a colloidal system or solution. Paste-like masses may display a Newtonian or a non-Newtonian flow behaviour.
- Active pharmaceutical ingredients (APls) that may be administered in accordance with such a titration scheme are or may be the following active ingredients in liquid or in paste-like form: uncompetitive channel blockers (e.g. NMDAr antabonists, e.g. amantadine, dextromethorphan, ibogaine, ketamine, phencyclidine, riluzole, memantine, neramexane), antagonists at α9/α10 nicotinic receptors (e.g. neramexane), non-competitive antagonists (e.g. dizocilpine, aptiganel, remacimide), glycine antagonists (e.g. 1-aminocyclopropanecarboxylic acid (ACPC), competitive antagonists (e.g. AP7 (2-amino-7-phosphonoheptanoic acid), thrombolytics (e.g. reteplase, tenecteplase, anistreplase, streptokinase, urokinase), anticoagulants (e.g. heparin, warfarin, acenocoumarol, phenprocoumon, phenindione, argatroban, lepirudin, bivalirudin), antibiotics, corticosteroids (e.g. beclomethasone, budesonide, betamethasone, ciclesonide, flunisolide, fluticasone, mometasone, refleponide, triamcinolone), antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine, abciximab, eptifibatide, tirofiban, cilostazol), non-stereoidal anti-inflammatories (NSAID) (e.g. salicylates (e.g. aspirin, amoxiprin, benorilate, choline magnesium salicylate, diflunisal, faislamine, methyl salicylate, magnesium salicylate, salicyl salicylate), arylalkanoic acids (e.g. diclofenac, aceclofenac, acemetacin, bromfenac, etodolac, indometacin, nabumetone, sulindac, tometin), 2-Arylpropionic acids (profens) (e.g. ibuprofen, carprofen, fenbufen, fenoporfen, flurbiprofen, ketoprofen, ketorolac, loxoprofen, naproxen, oxaprozin, tiaprofenic acid, suprofen), N-Arylanthranilic acids (fenamic acids) (e.g. mefenamic acid, meclofenamic acid), pyrazolidine derivates (e.g. phenylbutazone, azapropazone, metamizole, oxyphenbutazone, sulfinpyrazone), oxicams (e.g. piroxicam, lornoxicam, meloxicam, tenoxicam), COX-2 inhibitors (e.g. celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, valdecoxib), sulphonanilides (e.g. nimesulide)), growth factors (e.g. transforming growth factor beta (TGF-β), granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), nerve growth factor (NGF), neurotrophins, platelet derived growth factor (PDGF), erythropoietin (EPO), thrombopoietin (TPO), myostatin (GDF-8), growth differentiation factor-9 (GDF9), acidic fibroblast growth factor (aFGF or FGF-1), basic fibroblast growth factor (bFGF or FGF-2), epidermal growth factor (EGF), hepatocyte growth factor (HGF)), immunosuppressant drugs (e.g. cyclosporine, tacrolimus, prednisolone, azathioprine, sirolimus, mycopehnolate, glatiramer acetate), antineoplastic agents (alkylating agents (e.g. cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil), anti-metabolites (e.g. azathioprine, mercaptopurine, pyrimidine), vinca alkaloids (e.g. vincristine, vinblastine, vinorelbine, vindesine), podophyllotoxin (e.g. etoposide, teniposide), taxanes (e.g. paclitaxel), topoisomerase inhibitors (e.g. amsacrine, etoposide, etoposide phosphate, teniposide, camptothecins such as irinotecan, topotecan), antitumor antibiotics (e.g. dactinomycin), monoclonal antibodies (e.g. trastuzumab, cetuximab, rituximab, bevacizumab)), ACE-inhibitors (e.g. captopril, zofenopril, enalapril, ramipril, quinapril, perindopril, lisinopril, benazepril, fosinopril), Acetylcholinesterase Inhibitors (e.g. donepezil, rivastigmine, pyridostigmine, tetrahydroaminoacridine physostigmine, galantamine, tacrine, edrophonium, neostigmine), HMG-coA reductase inhibitors (e.g. atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, simvastatin), beta-blockers (e.g. alprenolol, carteolol, levobunolol, mepindolol, metipranolol, nadolol, oxprenolol, penbutolol, pindolol, propranolol, sotalol, timolol, acebutolol, atenolol, betaxolol, bisoprolol, esmolol, metoprolol, nebivolol, carvedilol, celiprolol, lavetalol, butaxamin), calcium channel blockers (e.g. verapamil, gallopamil, diltiazem, nimodipine, amlodipine, felodipine, nicardipine, nifedipine, nisoldipine, nitrendipine, lacidipine, lercandipine), long acting nitrates (e.g. isosorbide dinitrate and mononitrate, nitroglycerin) or cholesterol-lowering agents (e.g. bezafibrate, ciprofibrate, clofibrate, gemfibrozil, fenofibrate).
- According to one embodiment of the present invention, the kit comprising a liquid or paste-like pharmaceutical comprises at least one NMDA receptor antagonist. Such NMDAr antagonists may be compositions comprising, as pharmaceutically active ingredients, memantine or neramexane or pharmaceutically acceptable salts thereof.
- Another embodiment according to the present invention relates to a kit comprising a liquid or paste-like pharmaceutical comprising at least one acetylcholinesterase inhibitor (AchEI). Such acetylcholinesterase inhibitors may be compositions comprising, among others, donepezil, rivastigmine, pyridostigmine, tetrahydroaminoacridine, physostigmine, galantamine, tacrine, edrophonium, neostigmine and pharmaceutically acceptable salts thereof.
- In accordance with the present invention, no restrictions are made in regard to the composition of the fluid, liquid or paste-like substance that is being dispensed, other than that the fluid, liquid or paste-like substance must comprise at least one pharmaceutically active ingredient. Otherwise, the fluid, liquid or paste-like substance may include any other solvent, solute, additive, adjuvant or excipient that is pharmaceutically acceptable. According to one embodiment water and alcohol, or mixtures thereof, are used as solvent(s).
- Pump dispensers for dispensing liquids, viscous or paste-like masses, for example soap, lotion or condiments are known form the art. A simple-to-operate push plunger housed in a container is known, for example, from
US 3 463 093 . Another example of a general use dispensing unit is given inUS 5 326 000 . A dispenser or delivery apparatus for flowable media, particularly very viscous or gel-like media, specifically also comprising pharmaceuticals is disclosed inUS 4 728 008 . - In accordance with one embodiment of the present invention, the pump dispenser comprises at least one pump head and at least one reservoir attached thereto.
- According to one embodiment of the present invention, the pump head is of the "push-plunger"-type, i.e. comprises at least one plunger or piston or actuated pusher (actuator) and at least one sealed chamber in which a pressure can be built up by means of moving said plunger/piston/actuator.
- Dispensing by means of the "push-plunger"-principle is seen as particularly advantageous for operation of the dispenser by visually impaired patients or patients having coordination/motion control issues as is typical for some of the indications in accordance with the present invention, for example dementia, glaucoma, Alzheimer's disease etc. Droplet dispensers for liquids as known from pharmaceutical applications employing measuring spoons and/or narrow spouts for "counting" droplets are much less suitable for these indications/applications than the pump dispenser and kit in accordance with the present invention.
- In one embodiment according to the present invention, the pump dispenser dispenses said predetermined base-dosage essentially independent of the actuation path, and/or irrespective of how far the pump head has been actuated. In one embodiment, the amount of dispensed fluid is independent of how far the pump head (or, more specifically, the plunger) has been actuated once a predetermined threshold of the actuation path has been passed.
- In accordance with one embodiment of the present invention said threshold is defined by a recess in a chamber of the pump head of the dispenser.
- There are no restrictions in regard to the specific mechanic design for achieving this dosing of one specific and predetermined base-dosage as long as the same or at least a sufficiently similar dosage is provided per at least partially executed stroke.
- One possible technical realization for achieving a predetermined and reproducible dosage with one complete or one partially incomplete stroke is described in the following and illustrated by
Figure 1 showing an exemplary pump head / dosage head in accordance with the afore-described embodiment of the present invention. - The pump head comprises at least one hollow body (15) with a chamber (19) of a given inner diameter d15. This chamber contains the substance to be dispensed during the next cycle. This hollow body (15) also comprises a recess (20) with a diameter larger than d15. The hollow body furthermore comprises a conical seat and a second channel (22). This second channel is connected to a larger reservoir of the substance to be dispensed, i.e. the reservoir of the overall dispenser.
- A ball (21) is located in a conical seat of hollow body (15). Said ball (21) acts as a one-way valve and may seal off the second channel (22). Inside the hollow body (15) runs a piston (17) with a hollow stem (18) and an elastic lip at the lower end of piston (17). The hollow stem (18) comprises a first channel (27). A first spring (24) is provided between piston (17) and a shoulder of the hollow body (15). Said first spring (24) drives the piston away from the above-discussed reservoir. The hollow stem (18) has a compartment at its top to house the cone (28) and a second spring (29). This small compartment is open (35) to lead to any tube or applicator or spout for actually dispensing the fluid. Cone (28) is loaded by this second spring (29) and will close channel (27). Further details can be taken from
Figure 1 . - In the following, one mode of operation of this unit is explained. The cycle of dispensing the substance and refilling chamber (19) can be achieved as follows. Initially, chamber (19) is filled with the pharmaceutical substance to be dispensed. Springs (24) and (29) are not fully expanded. The second and first channels (22) and (27) are closed. The dispensing cycle is started by pushing the stem (18) into the hollow body (15). Meanwhile, piston (17) is driven further into the hollow body (15) thus increasing the chamber pressure. At the same time, spring (24) is being compressed.
- At a predetermined chamber pressure, the second spring (29) yields to said chamber pressure. This "yielding" can be adjusted (or "predetermined") by choosing an appropriate second spring (29). Coincidentally with the yielding of the second spring (29), the cone (28) opens the first channel (27). The pharmaceutical substance now flows out of chamber (19) through first channel (27) and opening (35), driven by the chamber pressure. Once the elastic lower lip of piston (17) reaches the recess (20) the chamber pressure collapses. This causes the second spring (29) to reposition cone (28) thus closing channel (27). This ends the dispensing step, irrespective of how the pump head is further actuated and/or how the plunger/piston is retracted. The dose (volume) of the supplied substance is determined by the inner diameter d15 of hollow body (15) and the distance covered by piston (17) before reaching the annular recess (20).
- Once the hollow stem (18) is released, first spring (24) will push piston (17) upwards along the hollow body (15). On its way up the elastic lower lip of piston (17) will exit the annular recess (20) and reengage with the inner diameter of the chamber (19) thus sealing said chamber. Further travel of piston (17) causes the chamber pressure to drop further. The reduced chamber pressure allows ball (21) to leave its conical seat, i.e. opens up the seal. The reduced chamber pressure draws fresh liquid or paste from the large reservoir into chamber (19) until the shoulder of stem (18) makes contact with bar (52). This contact of stem (18) and the bar (52) ends the cycle of operation.
- Therefore, in one embodiment of the present invention, the pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical comprises at least one pump head comprising a hollow body with a chamber of a defined inner volume and a defined inner diameter, wherein the hollow body further comprises a recess that has a diameter that is larger than said inner diameter of the chamber.
- While this mechanism is given as one example of how a predetermined amount of fluid can be dispensed with a high degree of reproducibility, this mechanism is only meant to serve as an example of the overall principle. The person skilled in the art readily knows of other mechanisms working in the same or in a similar manner.
- In one embodiment according to the present invention and in order to mitigate any potential (small) error in reproducibility in regard to the absolute volume dispensed (for example an error of a fraction of a millilitre), the overall dispensed volume per stroke (i.e. the volume of the predetermined base-dosage) is comparatively large, for example more than0.3 ml per stroke, more than 0.5 ml per stroke or more than 1 ml per stroke. As a consequence, in one embodiment according to the present invention, the volume as defined by the chamber inside the hollow body of the dispenser head is more than 0.3 ml, more than 0.5 ml or more than 1 ml.
- In one embodiment according to the present invention, while the volume dispensed per stroke is comparatively high, the concentration of the active ingredient in said predetermined dispensed volume is comparatively low, for example lower than 50 % (by volume), lower than 10 % or lower than 5 % or lower than 1 %. For example, 5 mg of active ingredient may be present in a base-dosage of 0.5 ml (resulting in a 1 % solution).
- By means of dispensing a comparatively large volume with a comparatively low concentration of active ingredient(s), any possible variation in dispensed volume per successive stroke translates only into a small variation in dispensed active ingredient, i.e. in base-dosage.
- Commonly used droplet bottles for dispensing liquid pharmaceuticals comprise a particularly narrow opening or spout through which only small droplets can be expelled. Due to the geometric constraint of the small opening and the action of surface tension, the volume of these small droplets is comparatively constant, albeit very small. In order to compensate for volume fluctuations and in order to achieve a final volume that can be reasonably administered, for example in a spoon, a large number of these small droplets needs to be dispensed in order to arrive at the one pre-described dosage, for example 20 droplets or 30 droplets. This administration scheme has a couple of draw-backs, in particular the requirement to count a large number of droplets. Therefore, such an administration scheme is not suitable for patients that are physically and/or mentally impaired. By contrast, the presently described pump-dispenser is designed to have an easy-to-use actuation head (as known, for example, from everyday usage soap dispensers) while dispensing the required base-dosage in one stroke. For example in a titration scheme requiring the administration of multiples of a base-dosage, for example two and three times the base-dosage, this may be achieved in the comparatively small number of two or three strokes (using a droplet-based dispenser as described above, for example the dispensing of two or three
times 20 droplets would be required to achieve the same result). - In one embodiment according to the present invention, the spout of the pump dispenser, i.e. the part of the pump head out of which the liquid, viscous or paste-like pharmaceutical is ultimately expelled is arcuate, i.e. has at least one portion that is substantially parallel in the horizontal direction and has at least one portion that is inclined in at least a 45 degree angle relative to the horizontal plane. This arcuate spout allows for a less spill-prone dispensing and is of particular advantage if the user of the dispenser is an older, handicapped or visually impaired patient.
Claims (16)
- Pharmaceutical kit comprising (i) a pump dispenser for dispensing multiples of a predetermined base-dosage of a liquid or paste-like pharmaceutical (ii) said liquid or paste-like pharmaceutical contained in said pump dispenser and (iii) instructions for implementing a predetermined titration scheme, wherein said titration scheme comprises the dispensing of at least two different integer multiples of said predetermined base-dosage.
- Kit according to claim 1, wherein said pump dispenser comprises at least a pump head and dispensing is achieved by means of actuating said pump head of said pump dispenser.
- Kit according to claim 1 or 2, wherein said pump dispenser comprises at least one pump head and at least one reservoir attached thereto and wherein the pump head comprises at least one plunger or piston or actuated pusher, i.e. actuator, and at least one sealed chamber in which a pressure can be built up by means of moving said plunger/piston/ actuator.
- Kit according to any one of the preceding claims, wherein said pump dispenser comprises at least one hollow body with a chamber of a defined inner volume and a defined inner diameter, wherein said hollow body comprises a recess that has a diameter that is larger than said inner diameter of the chamber.
- Kit according to claim 4, wherein the pump dispenser additionally comprises at least one ball acting as a one-way valve and at least one piston that runs inside the hollow body.
- Kit according claim 4, wherein the volume as defined by the chamber inside the hollow body of the dispenser head is more than 0.1 ml, more than 0.3 ml or ranges from 0.3 to 3 ml.
- Kit according to any one of the preceding claims, wherein the spout of the pump dispenser, i.e. the part of the pump head out of which the liquid or paste-like pharmaceutical is ultimately expelled has at least one portion that is substantially parallel to the horizontal plane and has at least one other portion that is inclined in at least a 45 degree angle relative to said horizontal plane.
- Kit according to any one of the preceding claims, wherein said dispensing of the base-dosage is achieved by performing one stroke of an actuator or plunge or piston of the pump head.
- Kit according to any one of preceding claims, wherein said liquid or paste-like pharmaceutical comprises at least one NMDA receptor antagonist and/or at least one acetylcholinesterase inhibitor and/or at least one α9/α10 nicotinic receptor antagonist.
- Kit according to claim 9, wherein the liquid or paste-like pharmaceutical comprises at least memantine and/or neramexane and/or pharmaceutically acceptable salts thereof.
- Kit according to any one of the preceding claims, wherein said titration scheme comprises the dispensing of at least two or at least three or at least four increasing integer multiples of said predetermined base-dosage.
- Kit according to claim 11, wherein said titration scheme comprises the dispensing of at least two increasing integers of the base-dosage with said integer starting at 1.
- Kit according to any one of the preceding claims, wherein said titration scheme comprises the dispensing of at least two or at least three or at least four decreasing integer multiples of said predetermined base-dosage.
- Kit according to claim 13, wherein the titration comprises at first the dispensing of an integer multiple n1 of a base-dosage and consecutively the dispensing of an integer multiple n2, wherein n2 < n1 and n1,n2 being > 1.
- Kit according to any one of the preceding claims, wherein said titration scheme comprises an interval therapy, i.e. comprises the dispensing of at least two or at least three or at least four alternating different dosages.
- Use of the kit according to any one of claims 1 to 15 for the treatment of a patient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09013034A EP2177275A1 (en) | 2008-10-16 | 2009-10-15 | Pump dispenser for the titration of pharmaceuticals |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19631308P | 2008-10-16 | 2008-10-16 | |
| EP08018154 | 2008-10-16 | ||
| EP09013034A EP2177275A1 (en) | 2008-10-16 | 2009-10-15 | Pump dispenser for the titration of pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2177275A1 true EP2177275A1 (en) | 2010-04-21 |
Family
ID=40510395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP09013034A Ceased EP2177275A1 (en) | 2008-10-16 | 2009-10-15 | Pump dispenser for the titration of pharmaceuticals |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2177275A1 (en) |
| WO (1) | WO2010043394A1 (en) |
Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3463093A (en) | 1967-01-17 | 1969-08-26 | Erich Pfeiffer Kg Metallwarenf | Simply operating push plunger pump housed in a container |
| US4565302A (en) * | 1983-01-22 | 1986-01-21 | Ing. Erich Pfeiffer Gmbh & Co. Kg | Actuatable dosing mechanism |
| US4728008A (en) | 1985-08-27 | 1988-03-01 | Ing. Erich Pfeiffer Gmbh & Co. Kg | Dispenser for flowable media |
| US5326000A (en) | 1991-03-16 | 1994-07-05 | Ing. Erich Pfeiffer Gmbh & Co. Kg | Medium dispenser with mounting support for optional secondary dispensing unit |
| US5918568A (en) * | 1996-08-26 | 1999-07-06 | Pharmalett Denmark A/S | Method of medicating and individualizing treatment shampoo for dermatological disturbances of companion animals |
| US20020066752A1 (en) * | 2000-10-16 | 2002-06-06 | Stefan Ritsche | Dispenser and method for discharging media |
| US6605060B1 (en) * | 1995-06-07 | 2003-08-12 | O'neil Alexander George Brian | Patient controlled drug delivery device |
| US20040050858A1 (en) * | 2002-07-13 | 2004-03-18 | Aero Pump Gmbh | Double-acting pump for ejecting a product from a container |
| US20040135002A1 (en) * | 2001-04-30 | 2004-07-15 | Klaus-Dieter Beller | Device for the spraying of fluids |
| US20060278557A1 (en) | 2003-07-16 | 2006-12-14 | Firestone Bruce A | Memantine titration/compliance dosage forms |
| US20070275145A1 (en) * | 2006-05-26 | 2007-11-29 | Catani Steven J | Method of delivering a high intensity sweetener to a liquid foodstuff |
-
2009
- 2009-10-15 EP EP09013034A patent/EP2177275A1/en not_active Ceased
- 2009-10-15 WO PCT/EP2009/007400 patent/WO2010043394A1/en not_active Ceased
Patent Citations (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3463093A (en) | 1967-01-17 | 1969-08-26 | Erich Pfeiffer Kg Metallwarenf | Simply operating push plunger pump housed in a container |
| US4565302A (en) * | 1983-01-22 | 1986-01-21 | Ing. Erich Pfeiffer Gmbh & Co. Kg | Actuatable dosing mechanism |
| US4728008A (en) | 1985-08-27 | 1988-03-01 | Ing. Erich Pfeiffer Gmbh & Co. Kg | Dispenser for flowable media |
| US5326000A (en) | 1991-03-16 | 1994-07-05 | Ing. Erich Pfeiffer Gmbh & Co. Kg | Medium dispenser with mounting support for optional secondary dispensing unit |
| US6605060B1 (en) * | 1995-06-07 | 2003-08-12 | O'neil Alexander George Brian | Patient controlled drug delivery device |
| US5918568A (en) * | 1996-08-26 | 1999-07-06 | Pharmalett Denmark A/S | Method of medicating and individualizing treatment shampoo for dermatological disturbances of companion animals |
| US20020066752A1 (en) * | 2000-10-16 | 2002-06-06 | Stefan Ritsche | Dispenser and method for discharging media |
| US20040135002A1 (en) * | 2001-04-30 | 2004-07-15 | Klaus-Dieter Beller | Device for the spraying of fluids |
| US20040050858A1 (en) * | 2002-07-13 | 2004-03-18 | Aero Pump Gmbh | Double-acting pump for ejecting a product from a container |
| US20060278557A1 (en) | 2003-07-16 | 2006-12-14 | Firestone Bruce A | Memantine titration/compliance dosage forms |
| US20070275145A1 (en) * | 2006-05-26 | 2007-11-29 | Catani Steven J | Method of delivering a high intensity sweetener to a liquid foodstuff |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010043394A1 (en) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6337084B2 (en) | Fluid dispenser device | |
| US8915889B2 (en) | Multiple dosage injector | |
| AU2026200283A1 (en) | Devices and methods for precision dose delivery | |
| KR101923331B1 (en) | Device and mehod for dispensing drug | |
| AU2009300898B2 (en) | A device for administering liquid analgesics | |
| WO2009086009A1 (en) | Dose counters and containers | |
| JP2012504999A5 (en) | ||
| JP2010538066A5 (en) | ||
| US20140203097A1 (en) | Selectively dispensing sprays | |
| EP2177275A1 (en) | Pump dispenser for the titration of pharmaceuticals | |
| EP4429803A1 (en) | Capsules and methods for mixing multiple substances | |
| US10709663B2 (en) | Mupirocin cream in pump device | |
| CA2756761C (en) | A multidose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical | |
| US11946788B2 (en) | Airless metered fluid dispenser assembly | |
| CA2413990A1 (en) | Acne-treating composition | |
| US10918574B2 (en) | Multi-chamber medicament dispensing device | |
| EP2280883A1 (en) | Device for containing and dosed delivering of at least one fluid | |
| EP2526925A1 (en) | A dose adjustable oral pump spray or aerosol spray containing memantine | |
| EP2942050A1 (en) | A sprayable oily composition based on liposoluble vitamins of the group d and use thereof | |
| WO2025186848A8 (en) | Apparatus for dispensing pharmaceutical products, over-the-counter drugs, supplements and the like | |
| JP2018108963A (en) | Liquid oropharyngeal medicine | |
| HK1161157A (en) | A device for administering liquid analgesics | |
| EA052025B1 (en) | DRUG DELIVERY DEVICE (OPTIONS) | |
| HK40029592B (en) | Devices and methods for precision dose delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA RS |
|
| 17P | Request for examination filed |
Effective date: 20100407 |
|
| 17Q | First examination report despatched |
Effective date: 20101014 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
| 18R | Application refused |
Effective date: 20161113 |